Faster cancer diagnosis by suspected cancer type

The share diagnosed or having cancer ruled out within 28 days, from breast and lung pathways to non-specific symptoms.

Embed this viewUpdated 16 Sept

Data access

Use the machine-readable JSON record or the flattened CSV download or the compact Markdown version.

Preview the latest 18 observations
SeriesPeriod or categoryValueUnit
ValueMissing or Invalid62.963% diagnosed or ruled out within 28 days · 2026-07
Valuehaematological malignancies (excluding acute leukaemia)72.0251% diagnosed or ruled out within 28 days · 2026-07
Valuelower gastrointestinal cancer72.3715% diagnosed or ruled out within 28 days · 2026-07
Valuegynaecological cancer74.3611% diagnosed or ruled out within 28 days · 2026-07
Valueurological malignancies (excluding testicular)75.5149% diagnosed or ruled out within 28 days · 2026-07
Valuecancer - non-specific symptoms75.836% diagnosed or ruled out within 28 days · 2026-07
Valueupper gastrointestinal cancer78.4445% diagnosed or ruled out within 28 days · 2026-07
Valuehead & neck cancer79.0306% diagnosed or ruled out within 28 days · 2026-07
Valueacute leukaemia81.8182% diagnosed or ruled out within 28 days · 2026-07
Valuelung cancer83.7186% diagnosed or ruled out within 28 days · 2026-07
Valuesarcoma85% diagnosed or ruled out within 28 days · 2026-07
Valuetesticular cancer87.3786% diagnosed or ruled out within 28 days · 2026-07
Valuechildren's cancer87.6543% diagnosed or ruled out within 28 days · 2026-07
Valueother cancer88.5246% diagnosed or ruled out within 28 days · 2026-07
Valuebreast cancer89.4673% diagnosed or ruled out within 28 days · 2026-07
Valueskin cancer91.9178% diagnosed or ruled out within 28 days · 2026-07
Valuebrain/central nervous system tumours93.4256% diagnosed or ruled out within 28 days · 2026-07
ValueExhibited (non-cancer) breast symptoms - cancer not initially suspected93.6597% diagnosed or ruled out within 28 days · 2026-07

Methodology

Latest provider-level Faster Diagnosis Standard activity, aggregated across NHS London-region providers by suspected cancer type. Rates use within-standard activity divided by total eligible activity. The lowest-performing pathway is ranked first; small pathways can move sharply month to month and the latest data are provisional.

Provenance

Cadence
monthly
Engine
comparison

Keep going